DelfaGLP-1 Atlas

Lead sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

9 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

9

Trials led

5

Active

5,364

Total enrollment

207

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
2
Phase 1/2
1
Phase 2
4
Phase 3
2

Trials by status

Not yet recruiting
2
Active, not recruiting
3
Completed
3
Unknown
1

Trials led

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)BMI ≥30Ph 3Not yet recruiting3,600
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)BMI ≥27Ph 3Not yet recruiting1,100
ACCESSBMI ≥30Ph 2Active, not recruiting220
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusBMI 27-40Ph 1/2Completed142
ACCESS IIBMI ≥30Ph 2Completed85
Aleniglipron Phase 2 Body Composition StudyBMI ≥30Ph 2Active, not recruiting71
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese ParticipantsBMI ≥27Ph 1Unknown70
GSBR-1290BMI ≥27Ph 2Active, not recruiting58
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants—Ph 1Completed18